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Background—Depression worsens the prognosis in patients with cardiac disease, and treatment with antidepressants may
improve survival. Guidelines recommend use of selective serotonin reuptake inhibitors (SSRIs), but knowledge of the
prognostic effect of different classes of antidepressants is sparse.
Methods and Results—We studied 99 335 patients surviving first hospitalization for heart failure (HF) from 1997 to 2005.
Use of HF medication and antidepressants (divided into tricyclic antidepressants [TCA] and SSRI) was determined by
prescription claims. Risk of overall and cardiovascular death associated with antidepressants, HF medication, and
coadministration of these 2 drug classes was estimated by Cox proportional hazard analyses. Propensity adjusted models
were performed as sensitivity analysis. During the study period, there were 53 988 deaths, of which 83.0% were due to
cardiovascular causes (median follow-up, 1.9 years; 5, 95% fractiles, 0.04 to 7.06 years). Use of -blockers was
associated with decreased risk of cardiovascular death (hazard ratio [HR], 0.77; 95% CI, 0.75 to 0.79). Antidepressants
were prescribed to 19 411 patients, and both TCA and SSRI were associated with increased risk of overall and cardiovascular
death (TCA: HR, 1.33; CI, 1.26 to 1.40; and HR, 1.25; CI, 1.17 to 1.32; SSRI: HR, 1.37; CI, 1.34 to 1.40; and HR, 1.34; CI,
1.30 to 1.38, respectively). Coadministration of SSRI and -blockers was associated with a higher risk of overall and
cardiovascular death compared with coadministration of -blockers and TCA (P for interaction 0.01).
Conclusions—Use of antidepressants in patients with HF was associated with worse prognosis. Coadministration of SSRIs
and -blockers was associated with increased risk of overall death and cardiovascular death compared with
coadministration of TCAs and -blockers. To further clarify this, clinical trials testing the optimal antidepressant
strategy in patients with HF are warranted. (Circ Heart Fail. 2009;2:582-590.)
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Heart failure (HF) constitutes a major health issue andoften requires lifelong treatment with multiple drugs.
Moreover, depression is common in patients with HF, and
25% of the patients receive antidepressant medication. This
is noteworthy because depression alone is known to worsen
the prognosis in HF.1–11 Various reasons for this observed
increased risk of death in depressed patients with HF have
been proposed: nonadherence to HF medication,12,13 smoking
and lack of exercise,14,15 greater catecholamine levels,16
increased serotonin and platelet activation,17 and antidepres-
sant toxicity.18–20 Polypharmaceutical treatment in patients
with HF has not been studied systematically, and because
depression is associated with a poorer prognosis, spontaneous
observations of interactions are unlikely.
Clinical Perspective on p 590
Studies have also suggested that treatment of depression
may improve prognosis in patients with HF, but this is
currently being tested in randomized trials.21–23 The impor-
tance of antidepressant therapy in a large real-life population
of patients with HF has not been investigated. However, 1
clinical trial has suggested a beneficial effect of antidepres-
sant therapy with a selective serotonin reuptake inhibitor
(SSRI) agent but only in patients having a substantial reduc-
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tion of depressive symptoms.24 Because the tricyclic antide-
pressants (TCAs) show side effects and proarrhythmic ef-
fects, caution is recommended by current guidelines, and
therefore, SSRIs have become the treatment of choice.25
However, these guidelines and practices are not clearly
substantiated by data but mainly inferred from the current
mechanistic knowledge of the drugs and results from few
observational studies.25 Recently, case studies have pointed
toward an unfavorable interaction between SSRI and
-blockers,18,20 and basic pharmacological studies indicate a
possible interaction.26–28 This prompted us to conduct a
nationwide cohort study of the effect of antidepressant use in
patients with HF and the prognostic importance. In addition,
we investigated the adherence to HF medication and interac-
tions between antidepressant and -blocker treatment.
Methods
Study Design
This study was a historical cohort study in patients with diagnosed
HF in Denmark from January 1, 1997, to December 31, 2005.
Patients were included in the study at discharge from their first
hospital admission with a discharge diagnosis of HF, and follow-up
was also started at that date. Outcome measures were death from all
causes and cardiovascular disease-specific deaths (International
Classification of Diseases [ICD] codes I00–I99).
Study Data
All residents in Denmark have a personal and unique personal
registration number, which enables linkage of administrative regis-
ters on the individual level. Vital status (dead or alive) was obtained
from The Danish Civil Registration System, which is updated every
second week. Causes of death were obtained from the National
Causes of Death Register in which immediate, contributory, and
underlying causes are recorded according to the ICD codes. Infor-
mation on concomitant medication was obtained from the National
Prescription Register (the Danish Register of Medicinal Product
Statistics) in which all claimed prescriptions in Denmark have been
recorded since 1995. The drugs are classified according to the
international Anatomic Therapeutical Chemical system. Because of
partial reimbursement of drug expenses by the healthcare system,
pharmacies in Denmark are required to register all dispensed
prescriptions in the National Prescription Register. This ensures a
highly accurate register.29 Comorbidity was obtained from the
Danish National Patient Register, which holds information on all
admissions to Danish hospitals since 1978.30 Each admission is
registered by 1 primary diagnosis and, if appropriate, 1 or more
secondary diagnosis according to the ICD—before 1994, the 8th
revision (ICD-8) and since 1994, the 10th revision (ICD-10).
Study Population
The Danish population aged 10 years or more on January 1, 1997,
constituted the base population. From 1997 to 2005, all individuals
who survived their first hospital admission for HF were included in
the study (ICD-10 codes: I11.0, I50, I42, and J81; as primary or
secondary diagnosis). First time admission for HF was defined as no
previous admission for HF since 1978. The discharge coding
diagnosis of HF has been validated in the Danish National Patient
Register and has high specificity but low sensitivity.31
Medical Treatment: Antidepressants
and -blockers
All prescriptions for -blockers (Anatomic Therapeutical Chemical
code C07) and antidepressants (TCA, Anatomic Therapeutical
Chemical code N06AA; SSRI, Anatomic Therapeutical Chemical
code N06AB) were obtained from the National Prescription Register.
Initiation of -blocker therapy subsequent to discharge was defined
as at least 1 claimed prescription within 90 days after discharge.
Baseline use of antidepressants was defined as at least 1 claimed
prescription for a TCA or a SSRI within 90 days before or 90 days
after discharge. For survival analyses, all treatment intervals accord-
ing to prescription data were located. The method used to determine
the dose and treatment duration has been described previously.32,33 In
brief, for each prescription, number of pills dispensed was divided by
the estimated daily dosage to calculate the treatment duration. This
method allowed the dosage to change according to refilling patterns
of consecutive prescriptions.
Statistical Analysis
Risk of all-cause death and cardiovascular death associated with the
use of -blockers, antidepressants, and a combination of both was
estimated by Cox proportional hazard analysis. Use of these drugs
was first defined as initiation of treatment in connection with the
admission for HF. To assess a more specific relationship between
exposure to the drugs and outcome, we also performed Cox propor-
tional hazard analysis with time-dependent variables for exposure.
Hence, the patients could change exposure status according to
prescription information. Finally, as sensitivity analyses, we per-
formed a stratified propensity-based analysis, ranking patients into
tertiles according to propensity of receiving -blockers within 90
days after discharge by logistic regression analysis conditional on
baseline covariates. The Cox models estimating the risk of cardio-
vascular death were censored for deaths resulting from causes
unrelated to the end point of interest (cardiovascular death, ICD code
I00-I99). All analyses were adjusted for available covariates (Table
1). The models were also adjusted for nonadherence in taking HF
medication. This was done as by Gislason et al34 by entering
time-dependent covariates into the model, allowing the patients to be
categorized as nonadherent when experiencing a break of 90 days or
more in treatment.
Multivariable analyses of time to first break in therapy with
-blockers, angiotensin-converting enzyme inhibitors and angioten-
sin-2 receptor antagonists (RASi), and spironolactone of 90 days
(representing nonadherence) were performed with Cox proportional
hazard models. All models were adjusted for available covariates
(Table 1). The assumptions underlying the Cox proportional hazard
regression analysis (assumption of linearity and no interaction) were
tested and found valid unless otherwise stated. To demonstrate
long-term adherence with HF medications according to the use of
antidepressant, we plotted the proportion of patients alive who were
on treatment on each day.
Unadjusted Kaplan–Meier curves were made according to the
baseline use of -blocker, TCA, and SSRI. For all analyses, a 2-sided
P value 0.05 was considered statistically significant. Cox propor-
tional hazard analyses with time-dependent variables were per-
formed using the Stata statistical package, version 10 (Stata Corp,
College Station, Tex). All other analyses and data management were
performed using SAS, version 9.1 (SAS Institute, Inc, Cary, NC).
Ethics
The Danish Data Protection Agency approved the study (No.
2003-54-1269). In Denmark, historical cohort studies based on data
from administrative registers do not require ethical approval.
Results
A total of 99 335 patients survived their first hospitalization
for HF during the study period. The median follow-up time
was 1.9 years (5, 95% fractiles, 0.04 to 7.06 years). The
baseline characteristics are shown in Table 1 according to
the type of antidepressant therapy used in connection with the
hospitalization for HF. In total, 980 patients received a
-blocker and TCA subsequent to discharge, and 4045
patients received SSRI and a -blocker. Substantially, more
women than men were prescribed with both types of antide-
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pressants, and patients treated with SSRIs tended to be older
than those treated with TCAs.
During the study period, 53 988 patients died (54.4%), of
whom 44 554 died of cardiovascular causes. One-year mor-
tality was 25.7% (25 557 patients). Of the 980 patients who
received a -blocker and TCA after discharge, 395 patients
died; of the 4045 patients who were prescribed with a
-blocker and SSRI after discharge, 1750 patients died. The
Kaplan–Meier curves are shown in Figures 1 and 2 according
to baseline initiation of -blockers and stratified by type of
antidepressant. Table 2 shows the results from the Cox
proportional hazard analysis demonstrating the association
between exposure to HF medication, TCA, and SSRI and the
occurrence of death and cardiovascular death (both baseline
and time-dependent exposure). The results show a protective
effect of -blockers on both outcomes, whereas use of both
types of antidepressants results in an increased risk with a
hazard ratio of 1. The SSRIs were associated with a
Table 1. Baseline Characteristics
TCA SSRI No TCA or SSRI Total
Patients (age, y) 3739 (72.611.6) 15672 (75.911.0) 80826 (73.912.4) 99335 (74.212.2)
Male (age, y) 1397 (69.611.6) 6544 (73.811.1) 43824 (71.212.5) 51457 (71.512.4)
Female (age, y) 2342 (74.411.2) 9128 (77.510.6) 36997 (77.111.4) 47873 (77.111.3)
Year of first hospitalization for HF
1997–1998 822 (22.0) 2652 (16.9) 17241 (21.3) 20502 (20.6)
1999–2000 843 (22.6) 3302 (21.1) 19059 (23.6) 23006 (23.2)
2001–2002 871 (23.3) 4004 (25.6) 18972 (23.5) 23643 (23.8)
2003–2004 827 (22.1) 3982 (25.4) 17478 (21.6) 22086 (22.2)
2005 376 (10.1) 1732 (11.1) 8076 (10.0) 10098 (10.2)
Discharge diagnosis at first HF hospitalization (ICD-10)
Hypertensive HF (I11.0) 91 (2.4) 391 (2.5) 2146 (2.7) 2604 (2.6)
Cardiomyopathy (I42) 157 (4.2) 453 (2.9) 4492 (4.6) 5056 (5.1)
Decompensated HF (I50.0 to I50.1) 1110 (29.7) 4757 (30.4) 23971 (29.7) 29562 (29.8)
Unspecified HF (I50.9) 2198 (58.8) 9352 (59.7) 47179 (58.4) 58222 (58.6)
Acute pulmonary edema (J81.9) 183 (4.9) 719 (4.6) 3038 (3.8) 3891 (3.9)
Comorbidity and history
Myocardial infarction 527 (14.1) 2877 (18.4) 15462 (19.1) 18723 (18.9)
Medically treated diabetes 334 (8.9) 1167 (7.5) 4600 (5.7) 6034 (6.1)
Ischemic heart disease 1076 (28.8) 4891 (31.2) 25137 (31.1) 30848 (31.1)
Cerebrovascular disease 463 (12.4) 3215 (20.5) 7677 (9.5) 11220 (11.3)
Peripheral vascular disease 419 (11.2) 1247 (8.0) 4881 (6.0) 6455 (6.5)
Malignancy 503 (13.5) 1872 (11.9) 8030 (9.9) 10295 (10.4)
Chronic obstructive pulmonary disease 682 (18.2) 3107 (19.8) 12596 (15.6%) 16204 (16.3)
Dementia 6 (0.2) 63 (0.4) 92 (0.1) 160 (0.2)
Renal failure 179 (4.8) 768 (4.1) 3423 (4.2) 4337 (4.4)
Severity group*
I 1018 (27.2) 4544 (29.0) 24150 (29.9) 29471 (29.7)
II 1483 (39.7) 6142 (39.2) 33182 (41.1) 40450 (40.7)
III 636 (17.0) 2585 (16.5) 13328 (16.5) 16394 (16.5)
IV 602 (16.1) 2401 (15.3) 10166 (12.6) 13020 (13.1)
Medical treatment after discharge
-blockers† 980 (26.2) 4045 (25.8) 26719 (33.1) 31515 (31.7)
RASi† 1586 (42.4) 6001 (38.3) 37280 (46.1) 44475 (44.8)
Spironolactone† 812 (21.7) 3280 (20.9) 16862 (20.9) 20751 (20.9)
Statin‡ 501 (13.4) 2172 (13.9) 13456 (16.7) 16015 (16.1)
Loop diuretic (furosemide)§ 3053 (81.7) 12621 (80.5) 63094 (78.1) 78034 (78.6)
Data are presented as n (meanSD) or n (%).
*According to average daily dosage of loop diuretic (furosemide) in the first 90 d after discharge (group I, 0 to 39 mg; group II, 40 to 80 mg; group III, 81 to 160
mg; and group IV, 160 mg).
†At least 1 prescription claimed within 90 d from discharge.
‡At least 1 prescription claimed within 180 d from discharge.
§At least 1 prescription claimed between 90 d before admission and 90 d after discharge.
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significantly higher risk of cardiovascular death compared
with TCAs.
Patients prescribed with TCA did not have an increased
risk of nonadherence with any of the HF medications,
whereas SSRI was associated with worse adherence to
-blockers and RASi compared with both TCA users and
patients taking no antidepressant medication (Table 3). The
long-term adherence to HF medication is illustrated by Figure
3A (adherence to -blockers), Figure 3B (RASi), and Figure
3C (spironolactone) according to the use of antidepressants.
We tested for difference in the effect of HF medication
(-blockers, RASi, and spironolactone) according to the type
of antidepressant used, and the results showed that there was
no difference in the importance of RASi and spironolactone
when taking either TCA or SSRI (all P for interaction
0.05). However, there was a difference in the importance of
-blockers according to the type of antidepressant used (P for
interaction 0.001 and 0.002 for overall death cardiovascular
death, respectively). Hazard ratios for death and cardiovas-
cular death according to treatment with -blockers and the
type of antidepressant are shown in Table 4. The results
showed that coadministration of SSRI and -blockers was
associated with increased risk of death and cardiovascular
death compared with the use of SSRI alone, TCA alone, and
TCA along with -blockers. Table 5 demonstrates the results
derived from the sensitivity analyses in which the model was
further adjusted for the patient’s probability of receiving
-blockers shortly after discharge (propensity stratified anal-
ysis conditional on baseline characteristics). The c statistic
was 0.78, indicating good discriminatory power of the model.
Results listed in Table 5 support the previous analyses and
underline the robustness of the results.
Additional Analyses
We performed sensitivity analyses for exposure to the most
frequently used types of -blockers because case reports on
interaction between SSRIs and -blockers have been reported
only on the specific -blocker, metoprolol. For metoprolol,
carvedilol, and bisoprolol, the results were very similar (data
not shown) to the results given in Tables 2, 4, and 5,
suggesting a class effect.
Discussion
This study has demonstrated that the use of antidepressants as
a proxy for depression carries an increased risk of death and
cardiovascular death among patients with HF. This increase
in risk was further potentiated when SSRIs were coadminis-
tered with -blockers as opposed to coadministration with
TCAs and -blockers. Although both types of antidepressants
were associated with increased risk of cardiovascular and
all-cause mortality, it seems that the risk associated with the
use of SSRIs is greater than that associated with TCAs. This
unexpected finding requires confirmation because case re-
ports have reported on possible adverse side effects of
combination therapy of only metoprolol and a SSRI.18,20 We
found no similar connection between the use of other
mortality-beneficial drugs in HF and antidepressants. In
addition, this study documented that the use of SSRIs was
associated with increased risk of nonadherence to evidence-
based pharmacotherapy in HF, whereas the use of TCAs did
not increase risk of nonadherence. Adherence to HF medica-
tion has also been proposed to be an important risk factor in
HF when depression is present as comorbidity,12,13,15 and our
study suggests that patients taking SSRI have an increased
risk of nonadherence to -blockers and RASi.
Other studies addressing the prognostic importance of
depression in patients with cardiac disease have shown that
depression is associated with a poor prognosis.1–6,15 This
study confirms that patients with HF have increased risk of
Figure 1. Unadjusted Kaplan–Meier curve according to use of
antidepressants, showing patients with heart failure who
claimed at least 1 prescription for a -blocker within 90 days of
discharge.
Figure 2. Unadjusted Kaplan–Meier curve according to use of
antidepressants. Patients with heart failure who did not claim a
prescription for a -blocker within 90 days of discharge.
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overall and cardiovascular death when treated with antide-
pressants, which we take as a proxy for depression. Currently,
several trials are testing the efficacy of antidepressive inter-
vention on outcome in various groups of patients with cardiac
disease.21–23 Current guidelines on the pharmacological ap-
proach to treating depression in patients with cardiac disease
state that, although data are lacking, it is recommended that
SSRIs are chosen before TCAs.25 This is, however, not based
on data but on the known adverse event profiles or efficacy
relation in depression without cardiac disease and the prob-
lems with the proarrhythmic risk associated with the TCAs.
One study has reported an increase in risk of myocardial
infarction associated with the use of TCAs,35 and it is also
known that TCAs prolong the QT interval and increase the
risk of sudden cardiac death.28,36,37 Furthermore, 1 head-to-
head study of nortriptyline compared with paroxetine in
patients with ischemic heart disease showed that patients
discontinued treatment with nortriptyline more often than
paroxetine because of cardiovascular adverse events.38 An-
other explanation for why we found worse prognosis associ-
ated with the use of SSRIs compared with TCAs may also be
that patients initiated on TCAs were healthier compared with
SSRI users, thus representing a selection bias. Another study
has reported decreased cardiovascular risk when treated with
SSRIs.39 On the contrary, Sherwood et al recently reported
that antidepressants carry an independent increase in risk
irrespective of depression in outpatients with HF, which is in
accordance with this study. In addition, only 1 small nonran-
domized study has recently investigated the importance of
coadministration of -blockers and antidepressants. The
study suggested that patients with end-stage HF and depres-
sion who were treated with SSRIs had better survival com-
pared with patients who were treated with TCAs.40 However,
this study was conducted on a large unselected cohort of
patients with HF with complete and nationwide data repre-
senting a real-life scenario. This discrepancy underlines the
fact that more studies are warranted on this subject. Overall,
previous studies question the safety of both TCAs and SSRIs
for the treatment of depression in patients with HF, but
confirmative data on this subject are lacking. An increased
risk of adverse outcome in patients treated with SSRI com-
pared with TCA could be explained by increased platelet
activation by serotonin or by direct stimulation of the myo-
cardium.41 Further studies need to assess whether treatment
with SSRIs increase the plasma level of serotonin enough to
stimulate the myocardium. Because depression is a major
comorbidity in HF with a possible survival benefit when
treated, it is crucial that the optimal treatment regimen is
found; whether or not this should be pharmacological is also
a relevant question. We believe that our study questions the
Table 2. Multivariable Adjusted HRs Derived From the Cox Proportional Hazard Analysis:
Standard Analysis and Time-Dependent Analysis
Standard Analysis
Analysis With Exposure
Entered in the Model as
Time-Dependent Variables
HR (95% CI) P HR (95% CI) P
Death
BB 0.68 (0.66 to 0.69) 0.0001 0.83 (0.81 to 0.86) 0.0001
Sprionolactone 1.13 (1.10 to 1.15) 0.0001 1.56 (1.52 to to.61) 0.0001
RASi 0.71 (0.70 to 0.73) 0.0001 0.72 (0.70 to 0.73) 0.0001
TCA 1.47 (1.39 to 1.54) 0.0001 1.33 (1.26 to 1.40) 0.0001
SSRI 1.51 (1.48 to 1.55) 0.0001 1.37 (1.34 to 1.40) 0.0001
Cardiovascular death
BB 0.80 (0.78 to 0.82) 0.0001 0.77 (0.75 to 0.78) 0.0001
Spironolactone 1.03 (1.01 to 1.06) 0.006 1.47 (1.43 to 1.50) 0.0001
RASi 0.80 (0.78 to 0.81) 0.0001 0.77 (0.75 to 0.78) 0.0001
TCA 1.00 (0.95 to 1.05) 0.88 1.25 (1.17 to 1.32) 0.0001
SSRI 1.09 (1.06 to 1.12) 0.0001 1.34 (1.30 to 1.38) 0.0001
The multivariable analysis is adjusted for age, sex, year of HF admission, comorbidity, concomitant pharmaco-
therapy, and severity of HF (Table 1). BB indicates at least 1 prescription claimed for a -blocker within 90 days from
discharge; RASi, at least 1 prescription claimed within 90 days from discharge of an angiotensin-converting enzyme
inhibitors and angiotensin-2 receptor antagonists; TCA, at least 1 prescription claimed for a tricyclic antidepressant
between 90 days before admission and 90 days after discharge; SSRI, at least 1 prescription claimed for a selective
serotonin reuptake inhibitor between 90 days before admission and 90 days after discharge.
Table 3. Multivariable Cox Proportional Hazard Analysis of
Time to First Break in Treatment of >90 Days (Proxy for
Nonpersistence) in HF
-Blockers, HR
(95% CI)
RASi, HR
(95% CI)
Spironolactone,
HR (95% CI)
No TCA
or SSRI
1.0 1.0 1.0
TCA 0.97 (0.88 to 1.06)* 1.04 (0.95 to 1.14)† 1.04 (0.94 to 1.14)‡
SSRI 1.31 (1.07 to 1.19)* 1.16 (1.10 to 1.22)† 1.02 (0.96 to 1.07)‡
*P0.007 for the difference between the hazard ratios for TCA versus SSRI.
†P0.04 for the difference between the hazard ratios for TCA versus SSRI.
‡P0.7 for the difference between the hazard ratios for TCA versus SSRI.
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use of SSRIs in combination with -blockers and that a large
clinical trial is crucial in analyzing risk and efficacy in the
treatment of depression among patients with HF. Further-
more, this results underline the prognostic importance of
depression in HF and demonstrate the need for more thorough
follow-up of these high-risk patients and the need for expert
care.
Currently, the mechanism by which a possible adverse
interaction between -blockers and SSRIs is established is
unknown. Several possibilities can be put forward. An inter-
action based on inhibition of -blocker metabolism in the
liver is a possibility because SSRIs have been shown to
inhibit the major pathway of elimination of some -blockers.
However, both types of drugs act on neurotransmitters and
nervous transmissions in both the brain and the heart, and
possibly in other organs as well. However, these mechanisms
are only speculative and not supported by solid data, which
can determine the plausibility. The results of this study
may possibly be explained by drug metabolism and by
drug action. In vitro studies have shown that SSRIs inhibit
CYP2D6, which mediates 60% of the biotransformation
of the -blocker metoprolol to -hydroxymetoprolol and
O-demethylmetoprolol in the human liver. Studies in human
liver microsomes suggest that -hydroxylation of metoprolol
Figure 3. Percentage of patients taking heart failure medication after discharge for heart failure illustrating the long-term adherence to
-blockers (A), RASi (B), and spironolactone (C) according to use of antidepressant medication. TCA indicates tricyclic antidepressants;
SSRI, selective serotonin reuptake inhibitors.
Table 4. Multivariable Adjusted HRs Derived From the Cox Proportional Hazard Analysis:
Standard Subgroup Analyses and Time-Dependent Analyses
Standard Analysis
Analysis With Exposure
Entered in the Model as
Time-Dependent Variables
HR (95% CI) P HR (95% CI) P
Death
Treatment with TCA and BB 1.13 (1.02 to 1.25) 0.02 1.46 (1.30 to 1.66) 0.0001
Treatment with TCA but no BB 1.12 (1.07 to 1.17) 0.0001 1.45 (1.36 to 1.55) 0.0001
Treatment with SSRI and BB 1.38 (1.31 to 1.45) 0.0001 1.47 (1.40 to 1.55) 0.0001
Treatment with SSRI but no BB 1.16 (1.13 to 1.19) 0.0001 1.31 (1.30 to 1.35) 0.0001
Cardiovascular death
Treatment with TCA and BB 1.10 (0.99 to 1.23) 0.1 1.28 (1.12 to 1.45) 0.001
Treatment with TCA but no BB 1.06 (0.99 to 1.11) 0.06 1.16 (1.08 to 1.24) 0.0001
Treatment with SSRI and BB 1.31 (1.24 to 1.38) 0.0001 1.37 (1.30 to 1.44) 0.0001
Treatment with SSRI but no BB 1.13 (1.10 to 1.17) 0.0001 1.18 (1.14 to 1.28) 0.0001
The multivariable analysis is adjusted for age, sex, year of HF admission, comorbidity, concomitant pharmaco-
therapy, adherence to HF medication, and severity of HF (Table 1). BB indicates -blockers.
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occurs almost exclusively, and O-demethylation partially,
through CYP2D6.42 A study on in vivo data indicates that
70% of the metabolism of metoprolol depends on
CYP2D6.43 Furthermore, we also know that biotransforma-
tion of metoprolol is inhibited by most SSRIs and SSRI
metabolites. Of these, fluoxetine, paroxetine, and norfluox-
etine are the most potent inhibitors.44
Furthermore, another explanation for the observed results
may be of opposite etiology: higher plasma levels of seroto-
nin due to a competitive relationship between SSRI and
-blockers in CYP450 enzyme oxidation. Higher levels of
serotonin in these patients with HF could pose a detrimental
effect on the myocardium as proposed by animal studies and
possibly increase risk of fibrosis and valvular disease.28,41
Furthermore, increased platelet activation by serotonin could
also be a mechanism in which prognosis may be affected by
higher levels of serotonin in plasma.17
It has not been studied whether the in vivo plasma
concentrations of metoprolol are increased when paroxetine
or fluoxetine are coadministered. Two case reports describing
an interaction between metoprolol and an SSRI (fluoxetine
and paroxetine) support this.18,20 Belpaire et al concluded that
fluoxetine, norfluoxetine, and paroxetine are potent inhibitors
of the in vitro metabolism of metoprolol, suggesting a
possible in vivo interaction; fluvoxamine, sertraline, and
citalopram are less potent inhibitors. In our study, we grouped
all -blockers as one, but as an additional analysis, we also
performed all analyses for metoprolol, carvedilol, and biso-
prolol separately to investigate the physiological etiology
of the pharmaceutical interaction. The results were similar
for all drugs, suggesting a class effect rather than an effect
valid only for metoprolol. Hence, the biological evidence
is currently sparse, but suggesting a plausible causative
relationship.
Strengths and Limitations
This study is based on complete and nationwide data. The
data cover the entire population of Denmark independent of
race, socioeconomic status, age, or participation in health-
insurance programs. Therefore, the risk of selection bias is
minimized, and the study notably includes citizens both in
and out of the labor market. The Danish healthcare system
partially reimburses drug expenses, and all Danish pharma-
cies are thus required to register all dispensed drug prescrip-
tions, which ensures complete registration. Furthermore,
because there is partial patient copayment of drug expenses in
Denmark, patients needing higher doses or long-term treat-
ment would have a financial incentive to obtain a prescription
from their physician to receive reimbursement. In Denmark,
all -blockers and antidepressants can be purchased only
through prescription.
The main limitation is inherited in the observational nature
of the study. We have no information about the precise
indication for initiation of antidepressant treatment. However,
we must assume that an individual prescribed with antide-
pressant medication has a relevant diagnosis constituting this
treatment. Another important limitation is the lack of detailed
information about important prognostic factors such as left
ventricular ejection fraction, New York Heart Association
classification, smoking status, systolic blood pressure, renal
function, serum sodium, and lipid levels. We have adjusted
the analyses for important comorbidity factors and concom-
itant pharmacotherapy; however, because this is an observa-
tional study, it is important to acknowledge that the effect of
unmeasured confounders cannot be completely excluded.
Therefore, the results observed in this study could perhaps be
explained by differences in patient characteristics and disease
severity described by covariates that are unavailable to us.
Furthermore, we cannot rule out the possibility that the
patients treated with TCAs in connection with their first
hospitalization for HF are indication-wise similar to patients
treated with SSRIs. However, all applied analyses showed
consistent results, and this underlines the robustness of the
findings. Because the current guidelines state that a SSRI
always should be preferred before a TCA, there is a possi-
Table 5. Propensity Score Adjusted Analyses: HRs Derived From the Cox Proportional Hazard
Analysis—Standard Subgroup Analyses and Time-Dependent Analyses Adjusted for Propensity
Score for Receiving -Blockers After Discharge
Standard Analysis
Analysis With Exposure
Entered in the Model as
Time-Dependent Variables
HR (95% CI) P HR (95% CI) P
Death
Treatment with TCA and BB 1.13 (1.02 to 1.26) 0.02 1.33 (1.18 to 1.51) 0.0001
Treatment with TCA but no BB 1.05 (0.99 to 1.10) 0.06 1.39 (1.40 to 1.59) 0.0001
Treatment with SSRI and BB 1.37 (1.29 to 1.45) 0.0001 1.36 (1.29 to 1.44) 0.0001
Treatment with SSRI but no BB 1.08 (1.05 to 1.10) 0.0001 1.26 (1.22 to 1.30) 0.0001
Cardiovascular death
Treatment with TCA and BB 1.05 (0.92 to 1.19) 0.6 1.10 (1.05 to 1.15) 0.0006
Treatment with TCA but no BB 1.00 (0.88 to 1.13) 0.7 1.10 (1.02 to 1.19) 0.008
Treatment with SSRI and BB 1.24 (1.16 to 1.33) 0.0001 1.30 (1.23 to 1.36) 0.0001
Treatment with SSRI but no BB 1.00 (0.96 to 1.04) 0.6 1.13 (1.09 to 1.17) 0.0001
The multivariable analysis is adjusted for age, sex, year of HF admission, comorbidity, concomitant pharmaco-
therapy, adherence to HF medication, and severity of HF (Table 1). BB indicates -blockers.
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bility that patients treated with TCAs have more severe
depression or have had depression for longer time than
patients treated with SSRIs. Furthermore, TCAs can poten-
tially prolong the QT interval, and therefore, an electrocar-
diographic control is part of the initiation of treatment with
these drugs. This could mean that patients with more severe
cardiac disease were less likely to be started on a TCA.
However, this difference in initiation of the type of antide-
pressant cannot explain the observed difference when the
patients are coadministrated with -blockers.
To assess a more accurate estimation of the association
between coadministration of the drugs and outcome, we used
several different statistical methods. Models with exposure
defined at baseline and as time-dependent variables gave
more or less the same result, and the propensity stratified
analyses underlined this. We ascribe the time-dependent
analysis more value because it takes into account the fluctu-
ating use of both antidepressants and -blockers in time.
Notably, risk of cardiovascular death was significantly higher
in individuals treated with SSRIs and -blockers compared
with those treated with TCAs and -blockers. This further
strengthens a causative relationship because an increase in
risk of all-cause death alone would support a confounding-
by-indication theory as explanation.
Conclusions and Implications
This study demonstrated that the use of SSRIs and TCAs in
connection with first hospitalization for HF is associated with
worse prognosis. The use of SSRIs was associated with a
higher increase in risk of overall mortality and cardiovascular
death compared with the use of TCAs. Furthermore, our
study raises concern on the coadministration of SSRIs and
-blockers in patients with HF. From an ethical point of view,
clarification from a randomized trial is warranted. We also
found an increased risk of nonadherence to HF medication
associated with the use of SSRIs but not with TCAs.
However, after adjusting for nonadherence, the overall results
were unchanged. Thus, the increased risk associated with
SSRI and -blocker use could not be explained by nonadher-
ence to lifesaving HF medication. Further investigations are
needed to clarify the importance of type of antidepressant
therapy in patients with HF needing -blockade.
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CLINICAL PERSPECTIVE
Depression is common in patients with heart failure (HF), and 25% of the patients receive antidepressant medication,
which is noteworthy because depression alone is known to worsen the prognosis in HF. Various reasons for this observed
increased risk of death in depressed patients with HF have been proposed, including nonadherence to HF medication;
smoking and lack of exercise; greater catecholamine levels; increased serotonin and platelet activation; and antidepressant
toxicity. In this study, we used Danish administrative registers to investigate the prognostic importance of antidepressant
therapy according to the type of antidepressants used among patients diagnosed with HF. Treatment of depression was
independently associated with worse prognosis, and selective serotonin reuptake inhibitors increased the risk of death and
cardiovascular death more than tricyclic antidepressants. Surprisingly, coadministration of serotonin reuptake inhibitors
and -blockers was associated with a higher risk of death and cardiovascular death compared with coadministration of
-blockers and tricyclic antidepressants. The findings were independent of adherence to HF medication, comorbidity,
concomitant pharmacotherapy, and HF severity and challenge the current guidelines. Hence, experimental investigations
are needed to clarify the importance of type of antidepressant therapy in patients with HF needing -blockade.
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